Durvalumab maintenance for unresectable NSCLC approved for UK patients
medwireNews: The UK’s NICE has recommended use of maintenance durvalumab therapy in patients with unresectable non-small-cell lung cancer (NSCLC) who have previously received concurrent platinum-based chemotherapy and radiation.
The announcement follows findings from the ongoing PACIFIC trial and therefore applies to patients with tumors expressing PD-L1 on at least 1% of tumor cells and whose disease has not progressed after platinum-based chemoradiation.
However, the PACIFIC results are not generalizable to NSCLC patients who have received sequential platinum-based chemotherapy and radiotherapy.
Maintenance use of the PD-L1 inhibitor durvalumab in the UK is recommended only through the Cancer Drugs Fund until further findings from PACIFIC are available on progression-free and overall survival with this agent.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group